Patients with moderate to severe Crohn's disease, who have failed prior treatment with the standard anti-TNF therapy will receive the study medication - MDGN-002 - which may help treat the Crohn's disease and relieve its symptoms.
The purpose of this research study is to be
studying the safety of this drug, including any side effects related to its use
and how well the symptoms are tolerated, while also learning if the study drug MDGN-002
might be useful in treating Crohn’s disease and its symptoms. . MDGN-002 is a
research therapy that has been tested before in adults using a single dose.
MDGN-002 is not yet approved by the United States Food and Drug Administration
How long will you be in this study?
If you agree to take part, the treatment
period will last for 84 days and will involve upto 12 study visits. Study
visits will last between 1 and 8 hours. There will be upto 2 study-related telephone
The total duration of being in the
study is about 26 weeks.
For additional information, please contact the study coordinator Rupa Chowdary at Rupa.firstname.lastname@example.org or 215-573-5073